Global Diabetic Neuropathy Market Report, published by Variant Market Research, forecast that the global market is expected to reach $3.8 billion by 2024 from $2.4 billion in 2016; growing at a CAGR of 5.9% from 2016 to 2024.

Diabetic Nephropathy Market (By Mode of Treatment: Drug Modifying Therapies, and Others; By Geography: North America, Europe, Asia-Pacific and RoW) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024

To browse the complete report, visit at https://www.variantmarketresearch.com/report-categories/pharmaceuticals/diabetic-nephropathy-market

Diabetic neuropathy denotes to the nerve damage caused because of diabetes. The disease most often damages nerves in the feet’s and legs. Though, it can injure nerve fibers throughout the body as well. Diabetic neuropathy is a most common complication of type 1 and type 2 diabetes. Growing diabetic population and increasing awareness among people for diabetes and related difficulties are some of the chief factors that are leading to the growth of diabetic neuropathy market.

Increasing cases of diabetes to drive the Diabetic Neuropathy market
Get Table of Content (TOC) @ https://www.variantmarketresearch.com/report-categories/pharmaceuticals/diabetic-nephropathy-market/toc
Some of the drivers or the factors leading to the growth of global diabetic nephropathy market are growing obesity and diabetes among population, mounting investments by major companies for drug discovery & development, rising number of patients suffering from numerous kidney diseases and rising awareness. Moreover, some initiatives by government and NGOs for growing awareness and rising scope of combination therapies would provide several growth opportunities.

Market Segmentation
Mode of treatment, and geography are the major segments of global Diabetic neuropathy market. Mode of treatment segment is further categorized into drug modifying therapies (angiotensin-converting enzyme (ACE) inhibitor, diuretics, calcium channel blockers (CCBs), angiotensin receptor blockers (ARBs), renin inhibitors, connective tissue growth factor inhibitor (CTGF), antioxidant inflammation modulator (AIM), monocyte chemoattractant proteins (MCP) inhibitors, endothelin-A receptors antagonist (ETAR), G protein-coupled receptors (GPCRs) and others) and others. Based on geography, the global diabetic neuropathy market has been segmented into North America, Europe, Asia-Pacific and Rest of the World (RoW).

Asia Pacific is anticipated to grow at a fastest CAGR over the forecast period
Asia Pacific is expected to attain the fastest CAGR during the forecast period 2016-2024, driven by the presence of high number of diabetic population, growing awareness and improving healthcare infrastructure. North America also held the largest market share of 41.1% in 2016, owning to well-developed economy and increasing demand at highest pace in the country.


Click Here to Request a Free Sample PDF of This Report @ https://www.variantmarketresearch.com/report-categories/pharmaceuticals/diabetic-nephropathy-market/sample-request

Competitive Landscape
Increasing mergers and acquisitions, quick product launches, and increase in number of collaborations and partnerships are some of the latest trends that have been detected in the global diabetic neuropathy market. Novartis, in 2015, had undergone collaboration with several other producers and supplier of diabetic neuropathy drug producers for expansion of their operations in developing countries.

The major players in the market includes Bayer AG, Novartis AG, Eli Lilly and Company, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Mesoblast Ltd., Ampio Pharmaceuticals Inc., Reata Pharmaceuticals, GenKyoTex S.A., and ChemoCentryx Inc., among others.

Scope of the Global Diabetic Nephropathy Market
Mode of Treatment Segments
• Drug Modifying Therapies (DMT)
o Angiotensin-Converting Enzyme (ACE) Inhibitor
o Angiotensin Receptor Blockers (ARBs)
o Diuretics
o Calcium Channel Blockers (CCBs)
o Renin Inhibitors
o Connective Tissue Growth Factor Inhibitor (CTGF)
o Antioxidant Inflammation Modulator (AIM)
o Monocyte Chemoattractant Proteins (MCP) Inhibitors
o Endothelin-A Receptors Antagonist (ETAR)
o G Protein-Coupled Receptors (GPCRs)
o Other Drug Modifying Therapies

• Other Mode of Treatments

Geography Segments
• North America
o U.S.
o Canada
o Mexico

• Europe
o UK
o Germany
o France
o Italy
o Other

• Asia-Pacific
o China
o Japan
o India
o South Korea
o Others

• RoW
o South America
o Middle East
o Africa

About Variant Market Research
Variant Market Research offers syndicated and customized reports to fulfill clients' objectives. We also provide customized data pack proposing market sizing in an Excel/PDF/PowerPoint or Word format as per the requirement of clients. We cover several industry domains, namely Semiconductor & Electronics, Consumer Electronics, Information and Communication Technology, Automotive, Consumer Goods, Food & Beverages, Pharmaceuticals, Medical Devices, Chemicals, Industrial, Mining Equipment, Automation, Manufacturing, Construction, Energy & Power, Defense & Aerospace and Banking, Financial services and Insurance (BFSI). Our expertise are data triangulation, competitor benchmarking, parent market benchmarking, estimating market size and forecast of the market from 2016 to 2024.
For further information, visit https://www.variantmarketresearch.com

Contact Us:
Michael Mendes
Head - Sales
Variant Market Research
649 Mission St, 5th Floor, San Francisco,
CA 94105,United States.
Tel: +1-415-680-2785
Fax: +1-415-680-2786
Email: [email protected]
Email: [email protected]